Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

Trial Profile

Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs CX 1739 (Primary) ; Remifentanil
  • Indications Respiratory insufficiency
  • Focus Therapeutic Use
  • Sponsors RespireRx Pharmaceuticals
  • Most Recent Events

    • 08 Sep 2017 According to a RespireRx Pharmaceuticals media release, results from this trial will be presented at the 2017 Rodman & Renshaw Conference.
    • 14 Jun 2017 According to a RespireRx Pharmaceuticals media release, results from this trial will be presented at the 2017 Marcum MicroCap Conference 2017.
    • 06 Jun 2017 According to a RespireRx Pharmaceuticals media release, results from this trial will be presented at the Sleep 2017 conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top